Pfizer Sees Celebrex Script Growth After Bextra Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
Script data indicates patients are switching from Bextra to Celebrex, Pfizer says. In the last three weeks, Celebrex has led the NSAID market in new prescription growth.